Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims are non-label topics (patents, pricing, preferences, timing of generic entry) or contain label-relevant clinical wording that is not supported by the provided prescribing information excerpts. Only limited clinical items (e.g., labeled indication for invasive aspergillosis, and that it is a posaconazole product with multiple dosage forms) are plausibly label-consistent from the excerpts, but several safety/administration/dosing details are either incorrect or not supported.
Category Scores
Accurate Statements
Noxafil received FDA approval in 2007.
Not supported or contradicted by the provided label excerpts.
Other antifungals such as posaconazole, amphotericin B, and caspofungin are available.
Not addressed in the provided label excerpts.
Unsupported Statements
Noxafil (voriconazole) is a specialty antifungal that treats rare, life-threatening infections.
Label excerpts provided are for Noxafil (posaconazole); the claim incorrectly identifies the active ingredient as voriconazole, and the provided excerpts do not support statements about 'rare, life-threatening infections' or 'specialty antifungal' terminology.
Noxafil’s active-ingredient patents expired in 2021.
Patents/expiration dates are not addressed in the provided label excerpts.
Noxafil’s formulation patents and marketing exclusivities have lagged behind the expiration of active-ingredient patents.
Marketing exclusivities/patent timing are not addressed in the provided label excerpts.
Remaining patents protect Noxafil’s specific oral and IV formulations and prevent generic competition for several years.
Patents/generic competition timing are not addressed in the provided label excerpts.
Patients and clinicians often prefer Noxafil for its oral availability and efficacy against Aspergillus species.
The provided label excerpts do not address patient/clinician preference or 'often prefer' statements.
Many insurers require prior authorization for Noxafil.
Insurance coverage/prior authorization is not addressed in the provided label excerpts.
Insurers negotiate rebates that can reduce the net price paid by payers for Noxafil.
Pricing/rebates are not addressed in the provided label excerpts.
Patient copay or coinsurance can still be substantial for Noxafil, especially on high-deductible plans.
Copay/coinsurance is not addressed in the provided label excerpts.
The negotiated price often stays high because the drug’s exclusivity and clinical utility give manufacturers pricing leverage.
Pricing rationale is not addressed in the provided label excerpts.
The manufacturer offers a patient assistance program that covers the cost for eligible patients.
Patient assistance program is not addressed in the provided label excerpts.
Some health systems provide institutional discounts or bulk purchasing agreements to lower institutional costs.
Institutional discount/bulk purchasing is not addressed in the provided label excerpts.
Generic competition is expected as formulation patents expire.
Generic entry timing/patent-related expectations are not addressed in the provided label excerpts.
Once a generic enters, the price will typically decline sharply.
Pricing/market behavior is not addressed in the provided label excerpts.
Generic entry timing depends on regulatory approvals and market dynamics.
Generic entry/market dynamics is not addressed in the provided label excerpts.
Noxafil’s high upfront R&D cost is recouped through pricing until generic competition erodes the margins.
R&D/pricing/margins are not addressed in the provided label excerpts.
Specialty drugs cover a larger portion of R&D costs per patient because their patient base is smaller.
General economic statements are not addressed in the provided label excerpts.
Noxafil’s pricing reflects a combination of therapeutic value, manufacturing complexity, and market exclusivity.
Pricing rationale is not addressed in the provided label excerpts.
Noxafil is a once-daily oral drug.
The provided label excerpts discuss administration requirements for oral suspension (with meals, within 20 minutes) but do not state that Noxafil is 'once-daily' for any labeled dosage form/indication.
Noxafil has a broad antifungal spectrum.
The provided label excerpts do not characterize Noxafil as having a 'broad antifungal spectrum' or list spectrum breadth.
Generic competition is expected as formulation patents expire.
Not addressed in provided label excerpts.
Contradictions
High
AI Statement
Noxafil (voriconazole) is a specialty antifungal that treats rare, life-threatening infections.
Label Reference
Drug and active ingredient(s) provided with the label excerpts indicate Noxafil (posaconazole). The label excerpts are for posaconazole.
Important Omissions
For any clinical use claims, the label excerpts specify labeled indications by dosage form/age/weight (e.g., invasive aspergillosis by specific forms/weights and prophylaxis by risk group; oropharyngeal candidiasis only for oral suspension and in patients 13+).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Incorrect active-ingredient identification (voriconazole vs posaconazole) is a material error. Additional unsupported statements about dosing frequency ('once-daily oral') and spectrum could mislead, though the provided label excerpts do not confirm these claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Active ingredient misidentification (voriconazole vs posaconazole) and multiple non-label claims (patents/pricing/insurance) plus unsupported clinical statements (once-daily oral; broad spectrum).
Suggested Improvement
Limit claims to what the label excerpts support: correct active ingredient as posaconazole; use only labeled indications by dosage form/age/weight; avoid patent/pricing/coverage statements; do not state dosing frequency or spectrum characterization unless explicitly present in the provided label excerpts.